Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) just unveiled an announcement.
Recordati has announced the availability of its 2024 Annual Financial Report, including the Draft Financial Statements and Consolidated Financial Statements as of December 31, 2024, along with various management and audit reports. These documents, approved by the Board of Directors, are accessible to the public via the company’s headquarters, website, and authorized storage mechanism. This release is part of the preparations for the Ordinary Shareholders’ Meeting scheduled for April 29, 2025, highlighting the company’s commitment to transparency and governance.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati is an international pharmaceutical group listed on the Italian Stock Exchange, with origins in a family pharmacy in Northern Italy in the 1920s. The company offers therapeutic options in specialty and general medicine, as well as in rare diseases, and operates in about 150 countries across the EMEA, Americas, and APAC regions with over 4,450 employees.
YTD Price Performance: 5.04%
Average Trading Volume: 34,046
Technical Sentiment Signal: Sell
Current Market Cap: €10.97B
See more insights into REC stock on TipRanks’ Stock Analysis page.